In light of the fact that the world is facing a persistent and increasing threat from counterfeit medicines, government leaders, politicians and executives from major pharmaceutical providers are driving efforts to develop methods to reliably track and trace medicinal products.
Based on this growing threat, the EU “Falsified Medicines Directive” as well as other globally enhanced legal requirements have defined a strong legal framework for the manufacturing and distribution of medicines. Reliable traceability and compliance with those rules are obligatory for pharmaceutical manufacturers who need to ensure product safety by keeping counterfeit medicines out of the legitimate supply chain.
Most pharmaceutical companies have already started to focus on implementing a serialization strategy and defining their needs as to production line serialization solutions in cooperation with trusted partners.
We have developed a guide that provides companies, in accordance with current or emerging serialization legislation, with crucial information on making an implementation decision by:
- Summarizing the minimum requirements of a serialization solution
- Outlining the complexity involved when implementing a serialization solution
- Detailed questions that must be addressed when choosing a production line equipment supplier.